anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: CID 163285897
Trial phase: Phase 3
ATC code: A10BX16
SMILES: CCC(C)C(NC(=O)C(CC(C)C)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(C)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(N)Cc1ccc(O)cc1)C(C)O)C(C)O)C(C)CC)C(C)CC)C(C)C)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N1CCCC1C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1CCCC1C(=O)N1CCCC1C(=O)N1CCCC1C(=O)NC(CO)C(N)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 159
Group description: Participants received 5 mg tirzepatide administered SC once weekly for 52 weeks.
Eligibility criteria:
Inclusion Criteria:

Participant must:

Have been diagnosed with type 2 diabetes mellitus based on the World Health Organization classification before the screening visit.

Have HbA1c meeting the following criteria, as determined by the central laboratory at screening and baseline:

for participants who are oral antihyperglycemic medication (OAM)-naïve at screening, ≥7.0% to ≤10.0% at both screening and baseline.
for participants who have been taking OAM monotherapy at screening, ≥6.5% to ≤9.0% at screening, and ≥7.0% to ≤10.0% at baseline.
Have body mass index (BMI) of ≥23 kilograms per meter squared at screening.
Be of stable weight (±5%) during 3 months preceding screening; and agree to not initiate an intensive diet and/or exercise program during the study with the intent of reducing body weight other than the lifestyle and dietary measures for diabetes treatment.

Exclusion Criteria:

Participant must not:

Have type 1 diabetes mellitus.
Have had chronic or acute pancreatitis any time prior to study entry.
Have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative diabetic retinopathy requiring immediate or urgent treatment.
Have disorders associated with slowed emptying of the stomach, or have had any stomach surgeries for the purpose of weight loss.
Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or blood alanine transaminase (ALT) enzyme level >3.0 times the upper limit of normal (ULN) for the reference range, as determined by the central laboratory. Participants with nonalcoholic fatty liver disease (NAFLD) are eligible for participation in this trial only if there ALT level is ≤3.0 the ULN for the reference range.
Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months.
Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2.
Have been taking weight loss drugs, including over-the-counter medications during the last 3 months.
Intervention: RISEDRONIC ACID
Trial phase: Phase 2
ATC code: M05BA07 | M05BB02 | M05BB04 | M05BB07
SMILES: O=P(O)(O)C(O)(Cc1cccnc1)P(=O)(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 41
Group description: Risedronate 150 mg given once 7-21 days prior to initiation of SBRT

risedronate: Risedronate 150 mg Oral Given once 7 - 21 days prior to initiation of SBRT
Eligibility criteria:
Inclusion Criteria:

Patients must be 18 years or older, but there is no upper limit on age of inclusion.
Patients must have a peripheral lung tumor that is amenable to SBRT as determined by the treating radiation oncologist. To be classified as a peripheral lung tumor, the tumor edge (the edge of the gross tumor volume or GTV in radiation treatment planning software) must be within 2 cm of the chest wall. This is determined by the treating radiation oncologist. The chest wall is defined as the chest wall musculature or ribs/vertebrae immediately adjacent to the lungs.
Patients must have ECOG status of 0-3
Patients must have a life expectancy of at least 3 months as determined by the treating radiation oncologist.
Patients must have the ability to understand and the willingness to sign an IRB-approved informed consent document.

Exclusion Criteria:

Prior radiation to any part of the body including the lungs or thorax is not an exclusion criteria

Tumor edge is greater than 2 cm from the chest wall. The edge of tumor is the edge of the gross tumor volume or GTV as defined in radiation treatment planning software. This is determined by the treating radiation oncologist.
Tumors that are expected to require more than 10 fractions of radiation as determined by the treating radiation oncologist.
History of using bone anti-resorptive agents including bisphosphonates or RANK-L inhibitors within the last 1 year.
Inability to stand or sit upright for at least 30 minutes, which is necessary for ingestion of risedronate.
Hypocalcemia defined as serum total calcium lower than 8.5 mg/dL on most recent bloodwork that is within 3 months of administration of study drug/placebo.
Severe renal impairment (EGFR <30 mL/min) on most recent bloodwork that is within 3 months of administration of study drug/placebo.
Known allergy to risedronate or other bisphosphonates
Surgery affecting the bone or dental operations within the last 6 months. This will be explicitly asked and documented in the EMR by treating radiation oncologist.
Dental operations do not include routine cleaning or cavity fillings
Dental operations that exclude patients refer to any manipulation of mandible.
Positive urine pregnancy test in women of child bearing potential within 1 week of registration. Pregnant women are excluded from this study because radiation has clear teratogenic and potentially abortifacient risks.
Intervention: Ketamine
Trial phase: Phase 4
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Patients received intravenous ketamine (0.5 mg/kg over 40 minutes) infusion during surgery.
Eligibility criteria:
Inclusion Criteria:

Patient presenting for non-cardiac, non-intracranial surgery
Major Depressive Disorder

Exclusion Criteria:

Pregnant of breastfeeding women
Intervention: Ketamine
Trial phase: Phase 4
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Patients received intravenous ketamine (0.5 mg/kg over 40 minutes) infusion during surgery.
Eligibility criteria:
Inclusion Criteria:

Patient presenting for non-cardiac, non-intracranial surgery
Major Depressive Disorder

Exclusion Criteria:

Pregnant of breastfeeding women
Intervention: Phenylephrine and ketorolac injection
Trial phase: Phase 4
SMILES: CNCC(O)c1cccc(O)c1.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 94
Group description: Phenylephrine/Ketorolac (1%/0.3%) will be administered to all participants enrolled into the study.

Omidria: Phenylephrine and Ketorolac infusion of 1%/0.3% during cataract surgery.
Eligibility criteria:
Inclusion Criteria:

Adults age 55-90 years with visual significant cataracts in one or both eyes.
Healthy individuals able to tolerate outpatient cataract surgery under local anesthesia via either phacoemulsification and/or femtosecond assisted cataract surgery. Well-controlled diabetes, hypertension will be included.
Females of childbearing potential must agree to use a reliable method of birth control while participating in this study. Reliable methods of birth control are: abstinence, oral contraceptives, intrauterine device (IUD), DepoProvera, tubal ligation or vasectomy of the partner (with confirmed negative sperm counts) in monogamous relationship (same partner). An acceptable, although less reliable, method involves the careful use of condoms and spermicidal foam or gel and/or cervical cap or sponge. A pregnancy test is required at least 10 days from the last normal menstrual period, if the patient is a sexually active female of childbearing potential.

Exclusion Criteria:

Allergy to Phenylephrine or NSAIDs.
Inability to sit steady and upright for the Optical Coherence Tomography (OCT).
Complications during surgery, including posterior capsular rupture, vitreous loss, zonular dialysis, or iris trauma.
Macular thickness above 300 microns at baseline
Currently taking a prostaglandin analogue
Presence of an epiretinal membrane on the preoperative OCT.
Retained lens fragment post-operatively.
Inability to return for follow appointments
Female patients who are pregnant, lactating or planning to become pregnant during the course of treatment.
Intervention: Allopurinol
Trial phase: Phase 2
ATC code: M04AA01 | M04AA51
SMILES: Oc1ncnc2[nH]ncc12
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.

Allopurinol: Allopurinol dosed to target uric acid levels of 3-5 mg/dL.
Eligibility criteria:
Inclusion Criteria:

Chronic Kidney Disease stage 1-5
Hyperuricemic (UA >= 5.5 mg/dL)

Exclusion Criteria:

Contraindication to Allopurinol
Elevated baseline liver function tests
Receiving acute or chronic dialysis
Primary metabolic disorder
Sickle cell disease
Autosomal Dominant Polycystic Kidney Disease
Cystinosis
Bartter or Gitelman Disease
Pregnant or nursing
Intervention: Dacomitinib
Trial phase: Phase 1
ATC code: L01EB07
SMILES: COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 16
Group description: Participants with normal hepatic function received a single oral dose of dacomitinib 30 mg tablet on Day 1 and were followed up to a maximum of 35 days for safety.
Eligibility criteria:
Inclusion Criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

Male and/or female participants of non childbearing potential must be 18 to 75 years of age, inclusive, at the time of signing the informed consent document (ICD).

Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.

Weight:

Body mass index (BMI) of 17.5 to 40 kg/m2; and a total body weight >50 kg (110 lb).
Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

Any condition possibly affecting drug absorption (eg, gastrectomy).
Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or IP administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
History of or current positive results for human immunodeficiency virus (HIV).
Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of IP used in this study (whichever is longer).
Hypersensitivity to dacomitinib or its excipients.
A positive urine drug test. Participants with severe hepatic impairment (Cohort 1) will be eligible to participate if their urine drug test is positive with a drug for a prescribed condition that is not expected to interfere with the PK of dacomitinib.
Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
History of sensitivity to heparin or heparin induced thrombocytopenia.
Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.
Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Sponsor employees, including their family members, directly involved in the conduct of the study.
Intervention: Resveratrol
Trial phase: Phase 2
SMILES: Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Participants who received Resveratrol 125 mg/day or 5 ml daily either the first or last 90 days of the study
Eligibility criteria:
Inclusion Criteria:

The diagnosis of pseudoachondroplasia is based on clinical assessment either in person or by photographic review by skeletal dysplasia specialist (JTH),
Healthy beyond pseudoachondroplasia associated complications,

Exclusion Criteria:

Current use of resveratrol
Current use of blood thinners, lovastatin, ketoconazole, itraconazole, fexofenadine and triazolam.
Other non-pseudoachondroplasia related health conditions, e.g. cancers.
Pregnancy or breastfeeding. Women must use adequate contraception during the study.
Participation in another clinical study and/or using investigational agents.
Use of Non-steroid anti-inflammatory (NSAIDs) or aspirin.
Current use of Alfentanil, Cyclosporine, Dihydroergotamine, Dofetilide, Ergotamine, Fentanyl, Flibanserin, Oxycodone, Pimavanserin, Pimozide, Quinidine, Saquinavir, Sirolimus, Tacrolimus, Temsirolimus, Theophylline, Tizanidine, Thioridazine, Fosphenytoin, Phenytoin or Warfarin.
Baseline level of pain of 2 or higher on 10 point scale.
Platelet count below 50,000 per ul on baseline complete blood count (CBC).
Intervention: Aztreonam
Trial phase: Phase 2 | Phase 3
ATC code: J01DF01
SMILES: CC1C(NC(=O)C(=NOC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 32
Group description: Subjects to receive 2g Aztreonam IM for the treatment of gonorrhea

Aztreonam: 2g IM Aztreonam
Eligibility criteria:
Inclusion Criteria:

Persons diagnosed with pharyngeal gonorrhea or gonococcal urethritis who are undergoing pharyngeal gonorrhea testing, who are not yet treated.

Exclusion Criteria:

Age less than 16 years
Receipt of antibiotics in ≤30 days
Known allergy to aztreonam
History of renal disease (including diagnosis of solitary kidney, chronic renal insufficiency, renal cell carcinoma etc.)
Concurrent infection with syphilis or chlamydia
Pregnancy and/or nursing
Unable to return for a follow-up visit 4-7 days (+/- 1 day).
Study team's discretion
Intervention: Opioid
Trial phase: Phase 4
SMILES: CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.CCOC(=O)C1(c2ccccc2)CCN(C)CC1.COc1ccc2c3c1OC1C(=O)CCC4(O)C(C2)N(C)CCC314
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 22
Group description: This group includes subjects with renal stones who are consented for a ureteroscopy. They will be randomized to Norco 5milligram-325milligram Tablet for postoperative pain after ureteroscopy with stent placement.

Norco 5milligram-325milligram Tablet: Designated coated 7 days supply of pain medication (Norco 5 milligram-325milligram Tablet) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times per day until the stent will be removed in clinic a week later.
Eligibility criteria:
Inclusion Criteria:

Ureteroscopy performed for renal stones
Age over 18 years
Two kidneys

Exclusion Criteria:

Solitary Kidney
Poor kidney function (GFR<30)
Allergy to either Ibuprofen or Norco
Pelvic Kidney
Intervention: Nicotine
Trial phase: Not Applicable
ATC code: N07BA01
SMILES: CN1CCCC1c1cccnc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 34
Group description: Participants will receive 10 weeks of nicotine patch (NRT) plus 8 weeks of task persistence focused cessation counseling delivered via telehealth.

Persistence Targeted Smoking Cessation in SMI (PTSC-S): All participants will receive 8 weeks of persistence focused smoking cessation counseling delivered via telehealth

Nicotine patch: All participants will receive 10 weeks of nicotine patch
Eligibility criteria:
Inclusion Criteria:

Must be between 18 - 70 years old
Must indicate willingness to make a quit attempt in the next 30 days
Must report being a daily cigarette smoker (including those labeled "little cigars") for past month
Must have a diagnosis of Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder on the Structured Clinical Interview for Diagnostic and Statistical Manual (DSM), 5th edition, Research Version (SCID-5-RV)
Psychiatric illness must be stable, as indicated by no hospitalizations in previous 8 weeks, and a stable psychotropic medication regimen for 8 weeks
Must have a smartphone, tablet, or computer with ability to download apps
Must currently receive mental health treatment
Must sign release of information for current mental health treatment providers

Exclusion Criteria:

Must not currently (in past 10 days) be taking varenicline (Chantix),
Must not currently (in past 10 days) be taking bupropion (Zyban/Wellbutrin) to quit smoking.
Must not be taking any nicotine preparations (gum, lozenge, patch, spray, inhaler) daily over the last 10 days
Must not report myocardial infarction, unstable angina pectoris, or significant cardiac arrhythmia (including atrial fibrillation) in the past 30 days.
Women must not be pregnant, "test positive" on a pregnancy test, nursing, or planning on becoming pregnant in the next three months. Women who can become pregnant may be included if using effective birth control.
Must not have pending legal matters with potential to result in jail time
Must not be planning on moving outside local area in next 3-months
Problematic substance use in the past 3 months (Alcohol Use Disorders Identification Test-Concise (AUDIT-C) ≥5 for men and ≥4 for women, Drug Abuse Screening Test (DAST-10) score of ≥4)
Must not have suicidal ideation in the past week with intent, plan, or access to method; must not have attempted suicide in the past year (as assessed on the SCID-RV)
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 37
Group description: Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique

Liposomal bupivacaine: Extended-release local anesthetic
Eligibility criteria:
Inclusion Criteria:

English-speaking women ages 18 and older undergoing posterior repair and/or perineorrhaphy at our institution for pelvic organ prolapse

Exclusion Criteria:

Planned regional anesthesia
Allergy or contraindication to bupivacaine
Allergy or contraindication to opioids
Allergy or contraindication to non-steroidal medications
Planned laparotomy
Chronic pain diagnosis and/or chronic narcotic use
Intervention: Dapagliflozin
Trial phase: Phase 3
ATC code: A10BD15 | A10BD21 | A10BD25 | A10BK01
SMILES: CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 252
Group description: Dapagliflozin 10 mg, given once daily per oral use.
Eligibility criteria:
Inclusion Criteria:

Provision of signed informed consent prior to any study specific procedures
Male or female, aged ≥40 years
Established documented diagnosis of symptomatic HFpEF (NYHA functional class II-IV), which has been present for at least 8 weeks
LVEF>40% and evidence of structural heart disease
Elevated NT-proBNP levels
Patients should receive background standard of care as described below: All patients will be treated according to locally recognised guidelines on standard of care treatment for patients with HFpEF. Therapy should have been individually optimised and stable for ≥4 weeks (this does not apply to diuretics) and include (unless contraindicated or not tolerated) treatment of co morbidities (including high blood pressure, ischaemic heart disease, atrial fibrillation/flutter).
6MWD≥100 metres and ≤425 metres at enrolment and randomization

Exclusion Criteria:

Presence of any condition that precludes exercise testing
Participation in a structured exercise training programme in the 1 month prior to screening or planned to start during the trial
Receiving therapy with an SGLT2 inhibitor within 4 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor
Type 1 diabetes mellitus
eGFR <25 mL/min/1.73 m2 (CKD-EPI formula) at enrolment, unstable or rapidly progressing renal disease at time of randomisation
Systolic BP <95 mmHg on 2 consecutive measurements
Systolic BP ≥160 mmHg if not on treatment with ≥3 blood pressure lowering medications or ≥180 mmHg irrespective of treatments, on 2 consecutive measurements
Current acute decompensated HF or hospitalisation due to decompensated HF <4 weeks prior to enrolment
MI, unstable angina, coronary revascularization ablation of atrial fibrillation/flutter, valve repair/replacement, implantation of a cardiac resynchronization therapy device within 12 weeks prior to enrolment or planned to undergo any of these operations after randomization.
Stroke or transient ischemic attack within 12 weeks prior to enrolment.
Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including COPD.
Previous cardiac transplantation or implantation of a ventricular assistance device or similar device, or implantation expected after randomization
HF due to infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, known genetic hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy/dysplasia, or uncorrected primary valvular disease